These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 28417640)

  • 21. Treatment of mannan-enhanced influenza B virus infections in mice with oseltamivir, ribavirin and viramidine.
    Smee DF; Wandersee MK; Wong MH; Bailey KW; Sidwell RW
    Antivir Chem Chemother; 2004 Sep; 15(5):261-8. PubMed ID: 15535048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The anti-viral activity of the complex glycyrrhizic acid-alpha-glutamyl-tryptophan against experimental lethal influenza infection in white mice caused by oseltamivir-resistant strain of the virus].
    Smirnov VS; Garshinina AV; Guseva VM; Kalinina NA; Shtro AA; Beliaevskaia SV; Anikin VB; Zarubaev VV
    Vopr Virusol; 2013; 58(5):19-26. PubMed ID: 24640167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunological effects of the orally administered neuraminidase inhibitor oseltamivir in influenza virus-infected and uninfected mice.
    Burger RA; Billingsley JL; Huffman JH; Bailey KW; Kim CU; Sidwell RW
    Immunopharmacology; 2000 Apr; 47(1):45-52. PubMed ID: 10708809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201.
    Sidwell RW; Smee DF; Huffman JH; Barnard DL; Bailey KW; Morrey JD; Babu YS
    Antimicrob Agents Chemother; 2001 Mar; 45(3):749-57. PubMed ID: 11181355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice.
    Tarbet EB; Maekawa M; Furuta Y; Babu YS; Morrey JD; Smee DF
    Antiviral Res; 2012 Apr; 94(1):103-10. PubMed ID: 22429564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utilization of alpha-1-acid glycoprotein levels in the serum as a parameter for in vivo assay of influenza virus inhibitors.
    Sidwell RW; Wong MH; Bailey KW; Barnard DL; Jackson MK; Smee DF
    Antivir Chem Chemother; 2001 Nov; 12(6):359-65. PubMed ID: 12018681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prophylactic and therapeutic combination effects of rimantadine and oseltamivir against influenza virus A (H3N2) infection in mice.
    Simeonova L; Gegova G; Galabov AS
    Antiviral Res; 2012 Aug; 95(2):172-81. PubMed ID: 22617756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [In vivo efficacy of Ingavirin against pandemic A (H1N1/09)v influenza virus].
    Shishkina LN; Nebol'sin VE; Skarnovich MO; Kabanov AS; Sergeev AA; Erdyneeva UB; Serova OA; Demina OK; Agafonov AP; Stavskiĭ EA; Drozdov IG
    Antibiot Khimioter; 2010; 55(5-6):32-5. PubMed ID: 21033472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combinations of 1,8-cineol and oseltamivir for the treatment of influenza virus A (H3N2) infection in mice.
    Lai YN; Li Y; Fu LC; Zhao F; Liu N; Zhang FX; Xu PP
    J Med Virol; 2017 Jul; 89(7):1158-1167. PubMed ID: 27966790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oseltamivir-zanamivir combination therapy is not superior to zanamivir monotherapy in mice infected with influenza A(H3N2) and A(H1N1)pdm09 viruses.
    Pizzorno A; Abed Y; Rhéaume C; Boivin G
    Antiviral Res; 2014 May; 105():54-8. PubMed ID: 24583158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of oral gavage treatment with ZnAL42 and other metallo-ion formulations on influenza A H5N1 and H1N1 virus infections in mice.
    Barnard DL; Wong MH; Bailey K; Day CW; Sidwell RW; Hickok SS; Hall TJ
    Antivir Chem Chemother; 2007; 18(3):125-32. PubMed ID: 17626596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low dose oral combination chemoprophylaxis with oseltamivir and amantadine for influenza A virus infections in mice.
    Masihi KN; Schweiger B; Finsterbusch T; Hengel H
    J Chemother; 2007 Jun; 19(3):295-303. PubMed ID: 17594925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses.
    Marjuki H; Mishin VP; Chesnokov AP; De La Cruz JA; Davis CT; Villanueva JM; Fry AM; Gubareva LV
    J Virol; 2015 May; 89(10):5419-26. PubMed ID: 25740997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, in silico studies, synthesis and in vitro evaluation of oseltamivir derivatives as inhibitors of neuraminidase from influenza A virus H1N1.
    Neri-Bazán RM; García-Machorro J; Méndez-Luna D; Tolentino-López LE; Martínez-Ramos F; Padilla-Martínez II; Aguilar-Faisal L; Soriano-Ursúa MA; Trujillo-Ferrara JG; Fragoso-Vázquez MJ; Barrón BL; Correa-Basurto J
    Eur J Med Chem; 2017 Mar; 128():154-167. PubMed ID: 28182988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oseltamivir boosts 2009 H1N1 virus infectivity in vitro.
    Lin X; Zhou J; Zhang Y; Wu J; Zhang F; Li Z; Zhang Y; Bi S; Shu Y; Wang Y
    Biochem Biophys Res Commun; 2009 Dec; 390(4):1305-8. PubMed ID: 19879239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiviral activity of Anaferon (pediatric formulation) in mice infected with pandemic influenza virus A(H1N1/09).
    Shishkina LN; Skarnovich MO; Kabanov AS; Sergeev AA; Olkin SE; Tarasov SA; Belopolskaya MV; Sergeeva SA; Epstein OI; Malkova EM; Stavsky EA; Drozdov IG
    Bull Exp Biol Med; 2010 Oct; 149(5):612-4. PubMed ID: 21165400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mammalian pathogenesis of oseltamivir-resistant pandemic (H1N1) 2009 influenza virus isolated in South Korea.
    Kwon D; Shin K; Kim SJ; Lee JY; Kang C
    Virus Res; 2014 Jun; 185():41-6. PubMed ID: 24657788
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection.
    Fukao K; Noshi T; Yamamoto A; Kitano M; Ando Y; Noda T; Baba K; Matsumoto K; Higuchi N; Ikeda M; Shishido T; Naito A
    J Antimicrob Chemother; 2019 Mar; 74(3):654-662. PubMed ID: 30476172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous peramivir inhibits viral replication, and leads to bacterial clearance and prevention of mortality during murine bacterial co-infection caused by influenza A(H1N1)pdm09 virus and Streptococcus pneumoniae.
    Onishi M; Kitano M; Taniguchi K; Homma T; Kobayashi M; Yoshinaga T; Naito A; Sato A
    Antiviral Res; 2015 May; 117():52-9. PubMed ID: 25752738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of P38 MAP kinase inhibition in a mouse model of influenza.
    Growcott EJ; Bamba D; Galarneau JR; Leonard VHJ; Schul W; Stein D; Osborne CS
    J Med Microbiol; 2018 Mar; 67(3):452-462. PubMed ID: 29458547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.